The cases of LCAT and apoA1 deficiencies demonstrate the diverse phenotypic spectrum of HDL-C-related metabolic disorders, highlighting how early genetic screening can guide clinical management and follow-up strategies. This evidence concerns the gene APOA1 and metabolic disease.